Login
$UPXI
$0.61 +$0.00 (0.53%) After hours

Consolidated balance sheets

In millions of USD, except per-share amounts
Q1 FY2027
As of Sep 30, 2026
Q4 FY2026
As of Jun 30, 2026
Q3 FY2026
As of Mar 31, 2026
Q2 FY2026
As of Dec 31, 2025
Q1 FY2026
As of Sep 30, 2025
Q4 FY2025
As of Jun 30, 2025
Q3 FY2025
As of Mar 31, 2025
Q2 FY2025
As of Dec 31, 2024
Q1 FY2025
As of Sep 30, 2024
Q4 FY2024
As of Jun 30, 2024
Q3 FY2024
As of Mar 31, 2024
Q2 FY2024
As of Dec 31, 2023
Q1 FY2024
As of Sep 30, 2023
Q4 FY2023
As of Jun 30, 2023
Q3 FY2023
As of Mar 31, 2023
Q2 FY2023
As of Dec 31, 2022
Q1 FY2023
As of Sep 30, 2022
Q4 FY2022
As of Jun 30, 2022
Q3 FY2022
As of Mar 31, 2022
Q2 FY2022
As of Dec 31, 2021
Cash
Accounts receivable, net
Inventory, net
Prepaid expenses and other receivables
Due from Bloomios
Due from VitaMedica transition
Due from VitaMedica
Prepaid expenses and other assets
Current assets of discontinued operations
Assets available for sale - Interactive offers current
Assets available for sale - Building
Assets available for sale - VitaMedica current
Assets available for sale - E-core current
Current digital assets at fair value
Purchase price receivable - VitaMedica
Purchase price receivable - E-core
Total current assets
Property and equipment, net
Intangible assets, net
Goodwill
Deferred tax asset
Investment in digital company
Digital assets at fair value, net of current
Digital assets at fair value, net of current portion
Other assets
Assets held for sale
Discontinued assets available for sale - Interactive offers
Discontinued assets available for sale - VitaMedica
Discontinued assets available for sale - E-core
Right-of-use asset, net
Total other assets
Total noncurrent assets
Total assets
Current liabilities
Accounts payable
Accrued compensation
Deferred revenue
Accrued compensation
Deferred revenue
Accrued liabilities
Accrued interest
Related party advances, net
Acquisition payable
Short-term treasury debt
Note payable on building for sale
Current portion of Cygnet subsidiary notes payable
Current portion of related party note payable
Current portion of convertible notes payable
Current portion of acquisition note payable - E-core
Line of Credit
Current portion of operating lease payable
Current liabilities of discontinued operations
Total current liabilities
Operating lease payable, net of current portion
Related party note payable
Note payable
Notes payable - Cygnet subsidiary
Convertible notes payable
Acquisition note payable - E-core
Convertible notes payable, net of current portion
Discontinued liabilities - Interactive offers
Discontinued liabilities - VitaMedica
Discontinued liabilities - E-core
Long-term contingent liabilities
Total long-term liabilities
Stockholders' equity (deficit)
Preferred stock, $0.00001 par value, 10,000,000 shares authorized, and 150,000 shares issued and outstanding
Common stock, $0.001 par value, 5,000,000 shares authorized, and 1,010,843 and 1,045,429 shares issued and outstanding, respectively
Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 88,428,457 and 78,702,358 shares outstanding, as of September 30, 2026 and June 30, 2026, respectively
Treasury stock, 416,226 and 0, as of December 31, 2025 and June 30, 2025, respectively
Additional paid in capital
Accumulated deficit
Total stockholders' equity attributable to Upexi, Inc.
Total stockholders' equity (deficit)
Total stockholders' equity
Total liabilities and stockholders' equity (deficit)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support